
TMCI Stock Forecast & Price Target
TMCI Analyst Ratings
Bulls say
Treace Medical Concepts Inc is positioned for potential revenue growth due to its innovative product offerings, particularly the Lapiplasty 3D Bunion Correction procedure and the new MIS Osteotomy system, which may gain greater traction in the market than previously estimated. The company has opportunities to increase revenue per procedure through enhanced sales of ancillary products, indicating a potential for improved financial performance. Furthermore, there is an increasing likelihood of a growth acceleration trajectory anticipated in the second half of 2025 through 2026, supported by the company's strategic updates and expanded offerings.
Bears say
Treace Medical Concepts is facing potential pricing pressures on its patented Lapiplasty 3D Bunion Correction procedure, which could jeopardize revenue estimates if these pressures are worse than anticipated. Additionally, the profitability of Lapiplasty for healthcare providers may not be as compelling as alternative procedures, such as traditional Lapidus Fusion and Osteotomies, potentially hindering the adoption rate of this technology. These factors contribute to a negative outlook on the company's financial performance and growth prospects in the competitive orthopaedic market.
This aggregate rating is based on analysts' research of Treace Medical Concepts and is not a guaranteed prediction by Public.com or investment advice.
TMCI Analyst Forecast & Price Prediction
Start investing in TMCI
Order type
Buy in
Order amount
Est. shares
0 shares